

# Peter Moritz Becher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7765746/publications.pdf>

Version: 2024-02-01

35  
papers

1,722  
citations

331670

21  
h-index

345221

36  
g-index

36  
all docs

36  
docs citations

36  
times ranked

2789  
citing authors

#	ARTICLE	IF	CITATIONS
1	Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. ESC Heart Failure, 2021, 8, 1295-1303.	3.1	69
2	Seasonal trends of incidence and outcomes of cardiogenic shock : findings from a large, nationwide inpatients sample with 441,696 cases. Critical Care, 2021, 25, 325.	5.8	1
3	Study design and rationale of the pAtients pResenTing with cOngenital heaRt diseAse Register (ARTORIAâ€). ESC Heart Failure, 2021, 8, 5542-5550.	3.1	4
4	Differences in the Treatment of Acute Coronary Syndrome in the Pre-COVID and COVID Era: An Analysis from Two German High-Volume Centers. Journal of Cardiovascular Development and Disease, 2021, 8, 145.	1.6	4
5	Risk prediction of in-hospital mortality in patients with venoarterial extracorporeal membrane oxygenation for cardiopulmonary support: The ECMO-ACCEPTS score. Journal of Critical Care, 2020, 56, 100-105.	2.2	27
6	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation. Circulation, 2020, 142, 2095-2106.	1.6	269
7	Clinical characteristics and outcomes of patients with adult congenital heart disease listed for heart and heartâ€™lung transplantation in the Eurotransplant region. Journal of Heart and Lung Transplantation, 2020, 39, 1238-1249.	0.6	8
8	Procedural volume and outcomes in patients undergoing VA-ECMO support. Critical Care, 2020, 24, 291.	5.8	32
9	Application of the SCAI classification in a cohort of patients with cardiogenic shock. Catheterization and Cardiovascular Interventions, 2020, 96, E213-E219.	1.7	122
10	Patient Characteristics, Treatment and Outcome in Non-Ischemic vs. Ischemic Cardiogenic Shock. Journal of Clinical Medicine, 2020, 9, 931.	2.4	28
11	Neuron-specific-enolase as a predictor of the neurologic outcome after cardiopulmonary resuscitation in patients on ECMO. Resuscitation, 2019, 136, 14-20.	3.0	33
12	Impella 5.0 therapy as a bridge-to-decision option for patients on extracorporeal life support with unclear neurological outcomes. European Journal of Cardio-thoracic Surgery, 2019, 56, 1031-1036.	1.4	27
13	Distinct Hemodynamic Changes After Interventional Mitral Valve Edgeâ€™toâ€™Edge Repair in Different Phenotypes of Heart Failure: An Integrated Hemodynamic Analysis. Journal of the American Heart Association, 2018, 7, .	3.7	7
14	Unloading of the Left Ventricle During Venoarterial Extracorporeal Membrane Oxygenation Therapy in Cardiogenic Shock. JACC: Heart Failure, 2018, 6, 1035-1043.	4.1	105
15	Venoarterial Extracorporeal Membrane Oxygenation for Cardiopulmonary Support. Circulation, 2018, 138, 2298-2300.	1.6	92
16	Role of Toll-like receptors and interferon regulatory factors in different experimental heart failure models of diverse etiology: IRF7 as novel cardiovascular stress-inducible factor. PLoS ONE, 2018, 13, e0193844.	2.5	26
17	Predictive value of long-term changes of growth differentiation factor-15 over a 27-year-period for heart failure and death due to coronary heart disease. PLoS ONE, 2018, 13, e0197497.	2.5	17
18	Cardiac Function Remains Impaired Despite Reversible Cardiac Remodeling after Acute Experimental Viral Myocarditis. Journal of Immunology Research, 2017, 2017, 1-17.	2.2	19

#	ARTICLE	IF	CITATIONS
19	Experimental Heart Failure Models and Their Pathophysiological Characterization. <i>BioMed Research International</i> , 2016, 2016, 1-3.	1.9	7
20	Epithelial-to-Mesenchymal Transition Enhances the Cardioprotective Capacity of Human Amniotic Epithelial Cells. <i>Cell Transplantation</i> , 2015, 24, 985-1002.	2.5	22
21	Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?" <i>World Journal of Cardiology</i> , 2015, 7, 544.	1.5	15
22	Effect of a Stable Angiotensin(1-7) Analogue on Progenitor Cell Recruitment and Cardiovascular Function Post Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	5
23	Combination of RNA Interference and Virus Receptor Trap Exerts Additive Antiviral Activity in Coxsackievirus B3-induced Myocarditis in Mice. <i>Journal of Infectious Diseases</i> , 2015, 211, 613-622.	4.0	17
24	Impaired Endothelial Regeneration Through Human Parvovirus B19-Infected Circulating Angiogenic Cells in Patients With Cardiomyopathy. <i>Journal of Infectious Diseases</i> , 2015, 212, 1070-1081.	4.0	34
25	Total Aortic Arch Replacement: Superior Ventriculo-Arterial Coupling with Decellularized Allografts Compared with Conventional Prostheses. <i>PLoS ONE</i> , 2014, 9, e103588.	2.5	18
26	Interleukin-23 Deficiency Leads to Impaired Wound Healing and Adverse Prognosis After Myocardial Infarction. <i>Circulation: Heart Failure</i> , 2014, 7, 161-171.	3.9	48
27	Cardioprotection by placenta-derived stromal cells in a murine myocardial infarction model. <i>Journal of Surgical Research</i> , 2013, 185, 70-83.	1.6	37
28	Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model. <i>Circulation: Heart Failure</i> , 2013, 6, 1239-1249.	3.9	241
29	Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?. <i>Cardiology Research and Practice</i> , 2013, 2013, 1-9.	1.1	14
30	Diagnosing heart failure with preserved ejection fraction. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 463-474.	1.6	9
31	Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. <i>Basic Research in Cardiology</i> , 2012, 107, 308.	5.9	66
32	Role of Heart Rate Reduction in the Prevention of Experimental Heart Failure. <i>Hypertension</i> , 2012, 59, 949-957.	2.7	69
33	Human Cardiac-Derived Adherent Proliferating Cells Reduce Murine Acute Coxsackievirus B3-Induced Myocarditis. <i>PLoS ONE</i> , 2011, 6, e28513.	2.5	44
34	Reduced Degradation of the Chemokine MCP-3 by Matrix Metalloproteinase-2 Exacerbates Myocardial Inflammation in Experimental Viral Cardiomyopathy. <i>Circulation</i> , 2011, 124, 2082-2093.	1.6	81
35	Renin Inhibition Improves Cardiac Function and Remodeling After Myocardial Infarction Independent of Blood Pressure. <i>Hypertension</i> , 2008, 52, 1068-1075.	2.7	91